Completed

Genetic Analysis of Parkinson's Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Synucleinopathies+6

+ Basal Ganglia Diseases

+ Brain Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Observational
Study Start: February 1997
See protocol details

Summary

Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: July 2, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: February 11, 1997

Actual date on which the first participant was enrolled.

Individuals, and where possible multiple family members, from families with inherited Parkinson's disease will be enrolled. We will also be enrolling people with sporadic Parkinson's disease. Known disease genes will be sequenced to look for mutations. In the event that no mutations are detected and there are samples from multiple family members, linkage analysis will be undertaken in an effort to identify a region or regions of the genome harboring defective genes that cause inherited Parkinson's disease. Candidate genes that reside in regions linked to the disease will be sequenced in effort to find mutations responsible for the disease. Genetic linkage studies will include all available, informative family members, while gene sequence analysis will be performed on affected individuals and spousal controls. In the event that we identify a mutation of clear pathogenicity in one of the known Parkinson's genes, we will contact all participating family members to notify them of the discovery of the gene that causes PD in their family and offer them individual counseling and testing in a CLIA approved lab. To assess any impact caused by the offer and subsequent pursuit of genetic testing we will be administering a questionnaire assessing psychological well-being prior to and following testing.

NCT00001640
Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: July 2, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

500 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

SynucleinopathiesBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinsonian DisordersParkinson Disease

Criteria

INCLUSION CRITERIA: Individuals age 18 or over from families in which an autosomal dominant form of Parkinson's disease is apparently being inherited. The diagnosis must be supported by accepted clinical criteria: tremor, bradykinesia, and responsiveness to L-DOPA. Unaffected family members will also be enrolled. Subjects must give consent. Parkinson's disease may be associated with dementia. Decisionally-impaired individuals will be enrolled.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, United StatesOpen National Institutes of Health Clinical Center, 9000 Rockville Pike in Google Maps
CompletedOne Study Center